Parliament Panel Criticizes Delay Of India Drugs Policy
This article was originally published in PharmAsia News
A Parliament panel is critical of India's drug department for delaying the final version of the National Pharmaceutical Policy 2006. The policy is intended to lower the price of drugs through expanded price controls. The Parliamentary Standing Committee on Chemical and Fertiliser noted the department had strongly endorsed the proposed policy in an annual report, but said the agency had done little since, holding only three meetings on the matter. The committee said part of the budget intended to follow up on the policy remains unspent while the policy review continues without end. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.